SEARCH

SEARCH BY CITATION

References

  • 1
    Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323: 10331039.
  • 2
    Holgate ST. The epidemic of allergy and asthma. Nature 1999;402: B2B4.
  • 3
    Fireman P. Understanding asthma pathophysiology. Allergy Asthma Proc 2003;24: 7983.
  • 4
    Busse WW, Rosenwasser LJ. Mechanisms of asthma. J Allergy Clin Immunol 2003;111: S799S804.
  • 5
    Venge P, Byström J, Carlson M, Håkansson L, Karawacjzyk M, Peterson C et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999;29: 11721186.
  • 6
    Amin K, Ludviksdottir D, Janson C, Nettelbladt O, Björnsson E, Roomans GM et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. Am J Respir Crit Care Med 2000;162: 22952301.
  • 7
    Amin K, Rinne J, Haahtela T, Simola M, Peterson CG, Roomans GM et al. Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years’ duration. J Allergy Clin Immunol 2001;107: 249257.
  • 8
    Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001;119: 13291336.
  • 9
    Haahtela T. Assessing airway inflammation: from guessing to quantitative measurements. Ann Med 2002;34: 7476.
  • 10
    Dahl R, Venge P, Fredens K. Eosinophils. In: BarnesPJ, RodgerIW, ThomsonNCC, editors. Asthma. Basic mechanisms and clinical management. London: Academic Press, 1992: 111124.
  • 11
    Ackerman SJ, Loegering DA, Venge P, Olsson I, Harley JB, Fauci AS et al. Distinctive cationic proteins of the human eosinophil granule: major basic protein, eosinophil cationic protein and eosinophil-derived neurotoxin. J Immunol 1983;131: 29772982.
  • 12
    Venge P. The monitoring of inflammation by specific cellular markers. Scand J Clin Lab Invest Suppl 1994;219: 4754.
  • 13
    Venge P, Roxin L-E, Olsson I. Radioimmunoassay of human eosinophil cationic protein. Br J Haematol 1977;37: 331335.
  • 14
    Venge P. Cell mediators as diagnostic tests in allergy. In: WüthrichB, editor. Highlights in allergy and clinical immunology. Seattle, Toronto, Bern, Göttingen: Hoegrefe & Huber Publishers, 1992: 279284.
  • 15
    Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989;83: 15511555.
  • 16
    Matsson P, Ahlstedt S, Venge P, Thorell J. Clinical impact of the monitoring of allergic inflammation. London: Academic Press Limited, 1991.
  • 17
    Venge P. Soluble markers of allergic inflammation. Allergy 1994;5: 128134.
  • 18
    Byström J, Garcia RC, Håkansson L, Karawajczyk M, Moberg L, Soukka J et al. Eosinophil cationic protein is stored in, but not produced by, peripheral blood neutrophils. Clin Exp Allergy 2002;32: 10821091.
  • 19
    Metso T, Venge P, Haahtela T, Peterson CG, Seveus L. Cell specific markers for eosinophils and neutrophils in sputum and bronchoalveolar lavage fluid of patients with respiratory conditions and healthy subjects. Thorax 2002;57: 449451.
  • 20
    Abu Ghazaleh RI, Dunnette SL, Loegering DA, Checkel JL, Kita H, Thomas LL et al. Eosinophil granule proteins in peripheral blood granulocytes. J Leukocyte Biol 1992;52: 611618.
  • 21
    Breton-Gorius J, Coquin Y, Guichard J. Cytochemical distinction between azurophils and catalase-containing granules in leukocytes. I. Studies in developing neutrophils and monocytes from patients with myeloperoxidase deficiency: comparison with peroxidase-deficient chicken heterophils. Lab Invest 1978;38: 2131.
  • 22
    Lehrer RI. The fungicidal mechanisms of human monocytes. I. Evidence for myeloperoxidase-linked and myeloperoxidase-independent candidacidal mechanisms. J Clin Invest 1975;55: 338346.
  • 23
    Kargi HA, Campbell EJ, Kuhn C. III. Elastase and cathepsin G of human monocytes: heterogeneity and subcellular localization to peroxidase-positive granules. J Histochem Cytochem 1990;38: 11791186.
  • 24
    Bennett RM, Kokocinski T. Lactoferrin content of peripheral blood cells. Br J Haematol 1978;39: 509521.
  • 25
    Figarella C, Sarles H. Lactoferrin, a protein of human pancreatic external secretion. Scand J Gastroenterol 1975;10: 449451.
  • 26
    Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000;1482: 298307.
  • 27
    Seveus L, Amin K, Peterson CG, Roomans GM, Venge P. Human neutrophil lipocalin (HNL) is a specific granule constituent of the neutrophil granulocyte. Studies in bronchial and lung parenchymal tissue and peripheral blood cells. Histochem Cell Biol 1997;107: 423432.
  • 28
    Hansen NE, Karle H. Elevated plasma lysozyme in Hodgkin's disease. An indicator of increased macrophage activity. Scand J Haematol 1979;22: 173178.
  • 29
    Konstan MW, Chen PW, Sherman JM, Thomassen MJ, Wood RE, Boat TF. Human lung lysozyme: sources and properties. Am Rev Respir Dis 1981;123: 120124.
  • 30
    Torsteinsdottir I, Håkansson L, Hällgren R, Gudbjörnsson B, Arvidson NG, Venge P. Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology (Oxford) 1999;38: 12491254.
  • 31
    Venge P. A critical look at blood samples in CB and COAD. In: PerssonCGA, BrattsandR, LaitinenLA, VengeP, editors. Inflammatory indices in chronic bronchitis. Basel, Boston, Berlin: Birkauser Verlag, 1990: 109120.
  • 32
    Fuller GM, Bunzel RJ, Woloski BM, Nham SU. Isolation of hepatocyte stimulating factor from human monocytes. Biochem Biophys Res Commun 1987;144: 10031009.
  • 33
    Björk A, Venge P, Peterson CG. Measurements of ECP in serum and the impact of plasma coagulation. Allergy 2000;55: 442448.
  • 34
    Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993;92: 313324.
  • 35
    Kanazawa H, Kurihara N, Otsuka T, Fujii T, Tanaka S, Kudoh S et al. Clinical significance of serum concentration of interleukin-8 in patients with bronchial asthma or chronic pulmonary emphysema. Respiration 1996;63: 236240.
  • 36
    Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153: 530534.
  • 37
    Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6: 13681370.
  • 38
    Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Nitric oxide in exhaled air. Eur Respir J 1996;9: 26712680.
  • 39
    Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343: 133135.
  • 40
    Kharitonov SA, Barnes PJ. Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers 2002;7: 132.
  • 41
    Pedroletti C, Zetterquist W, Nordvall L, Alving K. Evaluation of exhaled nitric oxide in schoolchildren at different exhalation flow rates. Pediatr Res 2002;52: 393398.
  • 42
    Paredi P, Kharitonov SA, Barnes PJ. Analysis of expired air for oxidation products. Am J Respir Crit Care Med 2002;166: S31S37.
  • 43
    Reimert CM, Ouma JH, Mwanje MT, Magak P, Poulsen LK, Vennervald BJ et al. Indirect assessment of eosinophiluria in urinary schistosomiasis using eosinophil cationic protein (ECP) and eosinophil protein X (EPX). Acta Trop 1993;54: 112.
  • 44
    Kristjánsson S, Strannegård IL, Strannegård Q, Peterson C, Enander I, Wennergren G. Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment. J Allergy Clin Immunol 1996;97: 11791187.
  • 45
    Wennergren G. Inflammatory mediators in blood and urine. Paediatr Respir Rev 2000;1: 259265.
  • 46
    Tauber E, Halmerbauer G, Frischer T, Gartner C, Horak F Jr, Veiter A et al. Urinary eosinophil protein X in children: the relationship to asthma and atopy and normal values. Allergy 2000;55: 647652.
  • 47
    Breuer K, Kapp A, Werfel T. Urine eosinophil protein X (EPX) is an in vitro parameter of inflammation in atopic dermatitis of the adult age. Allergy 2001;56: 780784.
  • 48
    Labbe A, Aublet-Cuvelier B, Jouaville L, Beaugeon G, Fiani L, Petit I et al. Prospective longitudinal study of urinary eosinophil protein X in children with asthma and chronic cough. Pediatr Pulmonol 2001;31: 354362.
  • 49
    Oymar K. High levels of urinary eosinophil protein X in young asthmatic children predict persistent atopic asthma. Pediatr Allergy Immunol 2001;12: 312317.
  • 50
    Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47: 2529.
  • 51
    Kelly MM, Keatings V, Leigh R, Peterson C, Shute J, Venge P et al. Analysis of fluid-phase mediators. Eur Respir J Suppl 2002;37: 24s39s.
  • 52
    Pin I, Freitag AP, O'Byrne PM, Girgis-Gabardo A, Watson RM, Dolovich J et al. Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses. Am Rev Respir Dis 1992;145: 12651269.
  • 53
    Virchow JC Jr, Kroegel C, Hage U, Kortsik C, Matthys H, Werner P. Comparison of sputum-ECP levels in bronchial asthma and chronic bronchitis. Allergy 1993;48: 112118.
  • 54
    Fahy JV, Liu J, Wong H, Boushey HA. Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: a method for studying allergic airway inflammation. J Allergy Clin Immunol 1994;93:10311039.
  • 55
    Koller DY, Urbanek R, Götz M. Increased degranulation of eosinophil and neutrophil granulocytes in cystic fibrosis. Am J Respir Crit Care Med 1995;152: 629633.
  • 56
    Pizzichini E, Pizzichini MMM, Efthimiadis A, Evans S, Morris MM, Squillace D et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996;154: 308317.
  • 57
    Pizzichini MMM, Pizzichini E, Clelland L, Efthimiadis A, Mahony J, Dolovich J et al. Sputum in severe exacerbations of asthma – kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997;155: 15011508.
  • 58
    Koller DY, Nething I, Otto J, Urbanek R, Eichler I. Cytokine concentrations in sputum from patients with cystic fibrosis and their relation to eosinophil activity. Am J Respir Crit Care Med 1997;155: 10501054.
  • 59
    Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997;155: 449453.
  • 60
    Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155: 542548.
  • 61
    Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M. Eosinophil cationic protein levels in induced sputum correlate with the severity of bronchial asthma. Chest 1997;112: 12411247.
  • 62
    Sorva R, Metso T, Turpeinen M, Juntunen-Backman K, Björksten F, Haahtela T. Eosinophil cationic protein in induced sputum as a marker of inflammation in asthmatic children. Pediatr Allergy Immunol 1997;8: 4550.
  • 63
    Shoji S, Kanazawa H, Hirata K, Kurihara N, Yoshikawa J. Clinical implication of protein levels of IL-5 in induced sputum in asthmatic patients. J Asthma 1998;35: 243249.
  • 64
    Koller DY, Nilsson M, Enander I, Venge P, Eichler I. Serum eosinophil cationic protein, eosinophil protein X and eosinophil peroxidase in relation to pulmonary function in cystic fibrosis. Clin Exp Allergy 1998;28: 241248.
  • 65
    Dahlen I, Janson C, Björnsson E, Stålenheim G, Peterson CG, Venge P. Inflammatory markers in acute exacerbations of obstructive pulmonary disease: predictive value in relation to smoking history. Respir Med 1999;93: 744751.
  • 66
    Hargreave FE, Leigh R. Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160: S53S57.
  • 67
    Maestrelli P, Richeldi L, Moretti M, Fabbri LM. Analysis of sputum in COPD. Thorax 2001;56: 420422.
  • 68
    Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey HA et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001;108: 753758.
  • 69
    Wilson NM, James A, Uasuf C, Payne DN, Hablas H, Agrofioti C et al. Asthma severity and inflammation markers in children. Pediatr Allergy Immunol 2001;12: 125132.
  • 70
    Dahlen I, Janson C, Björnsson E, Stålenheim G, Peterson CG, Venge P. Changes in inflammatory markers following treatment of acute exacerbations of obstructive pulmonary disease. Respir Med 2001;95: 891897.
  • 71
    Schmekel B, Ahlner J, Malmstrom M, Venge P. Eosinophil cationic protein (ECP) in saliva: a new marker of disease activity in bronchial asthma. Respir Med 2001;95: 670675.
  • 72
    Rasp G, Hochstrasser K. Tryptase in nasal fluid is a useful marker of allergic rhinitis. Allergy 1993;48: 7274.
  • 73
    Rasp G, Thomas PA, Bujia J. Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhinitis measured by eosinophil cationic protein levels in native nasal fluid and serum. Clin Exp Allergy 1994;24: 11511156.
  • 74
    Hurst DS, Venge P. Levels of eosinophil cationic protein and myeloperoxidase from chronic middle ear effusion in patients with allergy and/or acute infection. Otolaryngol Head Neck Surg 1996;114: 531544.
  • 75
    Hurst DS, Amin K, Seveus L, Venge P. Mast cells and tryptase in the middle ear of children with otitis media with effusion. Int J Pediatr Otorhinolaryngol 1999;49: S315S319.
  • 76
    Hurst DS, Venge P. Evidence of eosinophil, neutrophil, and mast-cell mediators in the effusion of OME patients with and without atopy. Allergy 2000;55: 435441.
  • 77
    Reimert CM, Poulsen LK, Bindslev-Jensen C, Kharazmi A, Bendtzen K. Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). J Immunol Methods 1993;166: 183190.
  • 78
    Venge P, Nilsson L, Nyström S-O, Åberg T. Serum and plasma measurements of neutrophil granule proteins during cardiopulmonary bypass. A model to estimate human turnover of lactoferrin and myeloperoxidase. Eur J Haematol 1987;39: 339345.
  • 79
    Jönsson UB, Byström J, Stålenheim G, Venge P. Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clin Exp Allergy 2002;32: 10921095.
  • 80
    Wolthers OD, Heuck C. Circadian variations in serum eosinophil cationic protein, and serum and urine eosinophil protein X. Pediatr Allergy Immunol 2003;14: 130133.